# TB-500 reported effects and safety — what the community says and what the science cautions > TB-500 reported effects from research-use communities alongside the safety cautions that the literature supports — injury recovery, injection-site reactions, WADA prohibition, and the cancer-biology concern. Research context only. Anecdotal reports from research-use communities, held alongside the safety cautions the literature actually supports. ## The short version TB-500 is used in research communities primarily for soft-tissue and injury recovery. People report that nagging tendon, ligament, and joint problems feel better and resolve faster than expected. Adverse effects are mostly mild: injection-site redness and temporary tiredness are the most common complaints. The honest state of evidence: these are personal accounts, not results from controlled human trials. No registered human clinical trial of the TB-500 fragment has been published. The biology behind it is real — the parent protein Thymosin Beta-4 (Tβ4) has reached Phase III in humans for corneal healing — but virtually all of that encouraging data used the full 43-amino-acid parent protein, not the 7-amino-acid fragment sold in research channels. Whether the fragment produces the same effects is genuinely unknown. The safety cautions below are worth reading before the community reports. ## What people report These signals come from peptide-user forums, wellness-clinic write-ups, and qualitative summaries of online discussions. They are **anecdotal, not clinical evidence** — self-reported, unblinded, and uncontrolled. No doses appear here because no dose recommendation exists in the published record. **Benefits most commonly reported:** - **Faster recovery from tendon, ligament, and muscle injuries** (very commonly reported). The main reason people in research-use communities reach for TB-500. Nagging soft-tissue injuries feel better and activity returns sooner than expected; timelines vary considerably. - **Less joint pain and stiffness, better range of motion** (frequently reported). Joints feeling looser and less achy after a few weeks, especially in people with general wear-and-tear stiffness. - **Improved overall flexibility and mobility** (frequently reported). A more resilient feeling during training, typically noticed around three to four weeks in — overlapping with the joint and injury reports. - **Reduced inflammation or calmed-down soreness** (occasionally reported). A vaguer, softer effect than the injury-recovery reports; a subset describes reduced post-workout soreness or swelling. - **Better wound and skin healing** (occasionally reported). Cuts or surgical sites seeming to heal more quickly — consistent with animal wound-healing data for the parent protein, though the community accounts are anecdotal. - **Hair regrowth or thicker hair** (rarely reported). A minor and inconsistent signal from a smaller group, often alongside other interventions. **Adverse effects mentioned:** - **Injection-site redness, swelling, or aching** (very commonly reported). The most common complaint — a small sore or slightly swollen spot, mild and usually gone within a day or two. Typical of injected peptides generally. - **Temporary tiredness or lethargy** (frequently reported). Sluggishness for a day or two, especially early on; most say it fades. - **Head rush, lightheadedness, or mild headache** (occasionally reported). Brief and self-resolving in most accounts. - **Brief flu-like feeling** (occasionally reported). Feeling run-down or slightly feverish in the first day or two — mild and short-lived. - **Nausea** (rarely reported). Tending to arise with larger amounts; not a common complaint. - **Heightened awareness of an existing injury or temporary mood changes** (rarely reported). Transient and without any documented clinical basis. ## Safety and cautions **Human safety in people is essentially unstudied.** There are no completed controlled human trials of the TB-500 heptapeptide for any use. A 2026 Sports Medicine review of unapproved peptides — explicitly listing TB-500 — concluded that such compounds show promise in animal models but carry scarce human safety data, potential for serious harm, and operate largely outside regulatory oversight [24]. The full-length parent protein was well tolerated to 1,260 mg intravenously in Phase I [11], but that safety envelope belongs to a different molecule. **Theoretical cancer and tumor-growth concern.** People with current or past cancer, or a strong family cancer risk, are the group most often flagged for caution. The parent protein thymosin beta-4 is overexpressed in several cancers and has been linked to tumor spread and to the growth of new blood vessels that feed tumors [25][26]. The same pro-migration and pro-angiogenic actions that may support tissue repair could, in principle, also support tumor progression. This risk has not been measured for the TB-500 fragment specifically, but the preclinical signal in the parent protein warrants acknowledgment. **Banned in competitive sport.** TB-500 is prohibited by the World Anti-Doping Agency under peptide hormone and growth-factor categories at all times. Anti-doping laboratories have developed validated methods to detect TB-500 and its breakdown products in biological samples [27]. A positive test can end an athlete's eligibility regardless of claimed recovery benefit. **Reported benefits may overstate what the peptide actually does.** An honest animal study found the opposite of the typical recovery narrative in one key case: in dystrophin-deficient mdx mice given thymosin beta-4 for six months, the number of regenerating muscle fibers increased, but muscle strength, cardiac function, and fibrosis were not improved [28]. More regeneration on paper did not translate into better function — a caution against assuming that felt improvements represent structural repair. **TB-500 is a fragment, not the full thymosin beta-4 protein.** TB-500 carries only the Ac-LKKTETQ actin-binding piece of the 43-amino-acid parent. Almost all encouraging efficacy research used the full-length molecule [29]. Applying the parent protein's results to the short fragment is an extrapolation that has not been confirmed in controlled studies; effects could be weaker or different. **Research-grade product quality is not guaranteed.** Material sold as TB-500 for research is not manufactured to medicine-grade standards, and identity, purity, and sequence can vary between suppliers [30]. Unknown purity adds an unpredictable risk on top of the peptide itself and makes any reported outcome difficult to interpret. **Theoretical cautions for surgery and bleeding contexts.** Because the parent protein influences blood-vessel formation and is released by platelets at injury sites, people approaching surgery or with clotting disorders may face uncertain effects. This has not been studied for TB-500 in humans and remains a mechanism-based precaution rather than a documented finding. **Theoretical caution in pregnancy, breastfeeding, and development.** Because TB-500 acts on cell movement and new blood-vessel growth — processes central to fetal and juvenile development — pregnant or breastfeeding individuals and anyone still growing fall into a precautionary group. There are no human safety data in these populations. --- An independent editorial reading of the peer-reviewed literature — not a clinic, not a vendor, not a recommendation.